



LIBRARIES
UNIVERSITY OF WISCONSIN - MADISON

Plendil advertisement.

[s.l.]: [s.n.], 1993

<https://digital.library.wisc.edu/1711.dl/KFJLYRQZKZKPE8M>

<http://rightsstatements.org/vocab/InC/1.0/>

The libraries provide public access to a wide range of material, including online exhibits, digitized collections, archival finding aids, our catalog, online articles, and a growing range of materials in many media.

When possible, we provide rights information in catalog records, finding aids, and other metadata that accompanies collections or items. However, it is always the user's obligation to evaluate copyright and rights issues in light of their own use.

Hypertension plus concomitant disorders?

First, do no harm.

PLENDIL – No significant effect on cardiac contractility. No significant effect on conductivity. No effect on cardiac output. No negative inotropic effect.*

PLENDIL – Suitable for a wide range of hypertensive patients, including those with hypercholesterolemia, arthritis, diabetes, impaired renal function, asthma or COPD.

PLENDIL – Few known drug interactions.†

PLENDIL – Worldwide experience: More than 800 million patient days worldwide.¹

PLENDIL – One of the least expensive dihydropyridine calcium channel blockers available today.²‡

The most common unwanted effects are peripheral edema and headache.

24-hour control



Plendil®

(felodipine) *Tablets, 2.5 mg,
5 mg, 10 mg*

Because you consider the whole patient.

* In clinical trials in hypertensive patients without clinical evidence of left ventricular dysfunction, no symptoms suggestive of a negative inotropic effect were noted; however, none would be expected in this population. Although acute hemodynamic studies in a small number of patients with NYHA Class II or III heart failure treated with felodipine have not demonstrated negative inotropic effects, safety in patients with heart failure has not been established.

† See PRECAUTIONS section of Prescribing Information.

‡ Based on the Average Wholesale Price (AWP) at the recommended starting dosages for each product. AWP is from a published price list and does not necessarily represent the actual price to pharmacists or consumers.

Please see brief summary of Prescribing Information on the next page.

BRIEF SUMMARY

PLENDIL® (FELODIPINE) EXTENDED-RELEASE TABLETS

Before prescribing, please consult full Prescribing Information.

INDICATIONS AND USAGE: PLENDIL® is indicated for the treatment of hypertension. PLENDIL may be used alone or concomitantly with other antihypertensive agents.

CONTRAINDICATIONS: PLENDIL is contraindicated in patients who are hypersensitive to this product.

PRECAUTIONS: General: Hypotension: Felodipine, like other calcium antagonists, may occasionally precipitate significant hypotension and rarely syncope. It may lead to reflex tachycardia which in susceptible individuals may precipitate angina pectoris. (See ADVERSE REACTIONS.)

Heart Failure: Although acute hemodynamic studies in a small number of patients with NYHA Class II or III heart failure treated with felodipine have not demonstrated negative inotropic effects, safety in patients with heart failure has not been established. Caution therefore should be exercised when using PLENDIL in patients with heart failure or compromised ventricular function, particularly in combination with a beta blocker.

Elderly Patients or Patients with Impaired Liver Function: Patients over 65 years of age or patients with impaired liver function may have elevated plasma concentrations of felodipine and may therefore respond to lower doses of PLENDIL. These patients should have their blood pressure monitored closely during dosage adjustment of PLENDIL and should rarely require doses above 10 mg. (See CLINICAL PHARMACOLOGY and DOSAGE AND ADMINISTRATION sections of complete Prescribing Information.)

Peripheral Edema: Peripheral edema, generally mild and not associated with generalized fluid retention, was the most common adverse event in the clinical trials. The incidence of peripheral edema was both dose- and age-dependent. Frequency of peripheral edema ranged from about 10 percent in patients under 50 years of age taking 5 mg daily to about 30 percent in those over 60 years of age taking 20 mg daily. This adverse effect generally occurs within 2-3 weeks of the initiation of treatment.

Information for Patients

Patients should be instructed to take PLENDIL whole and not to crush or chew the tablets. They should be told that mild gingival hyperplasia (gum swelling) has been reported. Good dental hygiene decreases its incidence and severity.

NOTE: As with many other drugs, certain advice to patients being treated with PLENDIL is warranted. This information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects.

Drug Interactions: Beta-Blocking Agents: A pharmacokinetic study of felodipine in conjunction with metoprolol demonstrated no significant effects on the pharmacokinetics of felodipine. The AUC and C_{max} of metoprolol, however, were increased approximately 31 and 38 percent, respectively. In controlled clinical trials, however, beta blockers including metoprolol were concurrently administered with felodipine and were well tolerated.

Cimetidine: In healthy subjects pharmacokinetic studies showed an approximately 50 percent increase in the area under the plasma concentration time curve (AUC) as well as the C_{max} of felodipine when given concomitantly with cimetidine. It is anticipated that a clinically significant interaction may occur in some hypertensive patients. Therefore, it is recommended that low doses of PLENDIL be used when given concomitantly with cimetidine.

Digoxin: When given concomitantly with felodipine the peak plasma concentration of digoxin was significantly increased. There was, however, no significant change in the AUC of digoxin.

Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (e.g., phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers. In such patients, the mean area under the felodipine plasma concentration-time curve was also reduced to approximately six percent of that observed in healthy volunteers. Since a clinically significant interaction may be anticipated, alternative antihypertensive therapy should be considered in these patients.

Other Concomitant Therapy: In healthy subjects there were no clinically significant interactions when felodipine was given concomitantly with indomethacin or spironolactone.

Interaction with Food: See CLINICAL PHARMACOLOGY, Pharmacokinetics and Metabolism section of complete Prescribing Information.

Carcinogenesis, Mutagenesis, Impairment of Fertility

In a two-year carcinogenicity study in rats fed felodipine at doses of 7.7, 23.1 or 69.3 mg/kg/day (up to 28 times' the maximum recommended human dose on a mg/m² basis), a dose-related increase in the incidence of benign interstitial cell tumors of the testes (Leydig cell tumors) was observed in treated male rats. These tumors were not observed in a similar study in mice at doses up to 138.6 mg/kg/day (28 times' the maximum recommended human dose on a mg/m² basis). Felodipine, at the doses employed in the two-year rat study, has been shown to lower testicular testosterone and to produce a corresponding increase in serum luteinizing hormone in rats. The Leydig cell tumor development is possibly secondary to these hormonal effects which have not been observed in man.

In this same rat study a dose-related increase in the incidence of focal squamous cell hyperplasia compared to control was observed in the esophageal groove of male and female rats in all dose groups. No other drug-related esophageal or gastric pathology was observed in the rats or with chronic administration in mice and dogs. The latter species, like man, has no anatomical structure comparable to the esophageal groove.

Felodipine was not carcinogenic when fed to mice at doses of up to 138.6 mg/kg/day (28 times' the maximum recommended human dose on a mg/m² basis) for periods of up to 80 weeks in males and 99 weeks in females.

Felodipine did not display any mutagenic activity *in vitro* in the Ames microbial mutagenicity test or in the mouse lymphoma forward mutation assay. No clastogenic potential was seen *in vivo* in the mouse micronucleus test at oral doses up to 2500 mg/kg (506 times' the maximum recommended human dose on a mg/m² basis) or *in vitro* in a human lymphocyte chromosome aberration assay.

A fertility study in which male and female rats were administered doses of 3.8, 9.6 or 26.9 mg/kg/day showed no significant effect of felodipine on reproductive performance.

Pregnancy: Pregnancy Category C

Teratogenic Effects: Studies in pregnant rabbits administered doses of 0.46, 1.2, 2.3 and 4.6 mg/kg/day (from 0.4 to 4 times' the maximum recommended human dose on a mg/m² basis) showed digital anomalies consisting of reduction in size and degree of ossification of the terminal phalanges in the fetuses. The frequency and severity of the changes appeared dose-related and were noted even at the lowest dose. These changes have been shown to occur with other members of the dihydropyridine class and are possibly a result of compromised uterine blood flow. Similar fetal anomalies were not observed in rats given felodipine.

In a teratology study in cynomolgus monkeys no reduction in the size of the terminal phalanges was observed but an abnormal position of the distal phalanges was noted in about 40 percent of the fetuses.

Nonteratogenic Effects: A prolongation of parturition with difficult labor and an increased frequency of fetal and early postnatal deaths were observed in rats administered doses of 9.6 mg/kg/day (4 times' the maximum human dose on a mg/m² basis) and above.

Significant enlargement of the mammary glands in excess of the normal enlargement for pregnant rabbits was found with doses greater than or equal to 1.2 mg/kg/day (equal to the maximum human dose on a mg/m² basis). This effect occurred only in pregnant rabbits and regressed during lactation. Similar changes in the mammary glands were not observed in rats or monkeys.

There are no adequate and well-controlled studies in pregnant women. If felodipine is used during pregnancy, or if the patient becomes pregnant while taking this drug, she should be apprised of the potential hazard to the fetus, possible digital anomalies of the infant, and the potential effects of felodipine on labor and delivery, and on the mammary glands of pregnant females.

Nursing Mothers

It is not known whether this drug is secreted in human milk and because of the potential for serious adverse reactions from felodipine in the infant, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use

Safety and effectiveness in children have not been established.

ADVERSE REACTIONS

In controlled studies in the United States and overseas approximately 3000 patients were treated with felodipine as either the extended-release or the immediate-release formulation.

The most common clinical adverse experiences reported with PLENDIL® (Felodipine) administered as monotherapy in all settings and with all dosage forms of felodipine were peripheral edema and headache. Peripheral edema was generally mild, but it was age- and dose-related and resulted in discontinuation of therapy in about 4 percent of the enrolled patients. Discontinuation of therapy due to any clinical adverse experience occurred in about 9 percent of the patients receiving PLENDIL, principally for peripheral edema, headache, or flushing.

Adverse experiences that occurred with an incidence of 1.5 percent or greater during monotherapy with PLENDIL without regard to causality are compared to placebo in the table below.

Percent of Patients with Adverse Effects in Controlled Trials of PLENDIL as Monotherapy (incidence of discontinuations shown in parentheses)

Adverse Effect	PLENDIL % N = 730	Placebo % N = 283
Peripheral Edema	22.3 (4.2)	3.5
Headache	18.6 (2.1)	10.6
Flushing	6.4 (1.0)	1.1
Dizziness	5.8 (0.8)	3.2
Upper Respiratory		
Infection	5.5 (0.1)	1.1
Asthenia	4.7 (0.1)	2.8
Cough	2.9 (0.0)	0.4
Paresthesia	2.5 (0.1)	1.8
Dyspepsia	2.3 (0.0)	1.4
Chest Pain	2.1 (0.1)	1.4
Nausea	1.9 (0.8)	1.1
Muscle Cramps	1.9 (0.0)	1.1
Palpitation	1.8 (0.5)	2.5
Abdominal Pain	1.8 (0.3)	1.1
Constipation	1.6 (0.1)	1.1
Diarrhea	1.6 (0.1)	1.1
Pharyngitis	1.6 (0.0)	0.4
Rhinorrhea	1.6 (0.0)	0.0
Back Pain	1.6 (0.0)	1.1
Rash	1.5 (0.1)	1.1

In the two dose response studies using PLENDIL as monotherapy, the following table describes the incidence (percent) of adverse experiences that were dose-related. The incidence of discontinuations due to these adverse experiences are shown in parentheses.

Adverse Effect	Placebo N = 121	2.5 mg N = 71	5.0 mg N = 72	10.0 mg N = 123	20 mg* N = 50
Peripheral Edema	2.5 (1.6)	1.4 (0.0)	13.9 (2.8)	19.5 (2.4)	36.0 (10.0)
Palpitation	0.8 (0.8)	1.4 (0.0)	0.0 (0.0)	2.4 (0.8)	12.0 (8.0)
Headache	12.4 (0.0)	11.3 (1.4)	11.1 (0.0)	18.7 (4.1)	28.0 (8.0)
Flushing	0.0 (0.0)	4.2 (0.0)	2.8 (0.0)	8.1 (0.8)	20.0 (8.0)

*exceeds the maximum recommended daily dose.

In addition, adverse experiences that occurred in 0.5 up to 1.5 percent of patients who received PLENDIL® (Felodipine) in all controlled clinical studies (listed in order of decreasing severity within each category) and serious adverse events that occurred at a lower rate or were found during marketing experience (those lower rate events are in italics) were: *Body as a Whole:* Facial edema, warm sensation; *Cardiovascular:* Tachycardia, myocardial infarction, hypotension, syncope, angina pectoris, arrhythmia; *Digestive:* Vomiting, dry mouth, flatulence; *Hematologic:* Anemia; *Musculoskeletal:* Arthralgia, arm pain, knee pain, leg pain, foot pain, hip pain, myalgia; *Nervous/Psychiatric:* Depression, anxiety disorders, insomnia, irritability, nervousness, somnolence; *Respiratory:* Bronchitis, influenza, sinusitis, dyspnea, epistaxis, respiratory infection, sneezing; *Skin:* Contusion, erythema, urticaria; *Urogenital:* Decreased libido, impotence, urinary frequency, urinary urgency, dysuria.

Felodipine, as an immediate release formulation, has also been studied as monotherapy in 680 patients with hypertension in U.S. and overseas controlled clinical studies. Other adverse experiences not listed above and with an incidence of 0.5 percent or greater include: *Body as a Whole:* Fatigue; *Digestive:* Gastrointestinal pain; *Musculoskeletal:* Arthritis, local weakness, neck pain, shoulder pain, ankle pain; *Nervous/Psychiatric:* Tremor; *Respiratory:* Rhinitis; *Skin:* Hyperhidrosis, pruritus; *Special Senses:* Blurred vision, tinnitus; *Urogenital:* Nocturia.

Gingival Hyperplasia: Gingival hyperplasia, usually mild, occurred in <0.5 percent of patients in controlled studies. This condition may be avoided or may regress with improved dental hygiene. (See PRECAUTIONS, Information for Patients.)

Clinical Laboratory Test Findings

Serum Electrolytes: No significant effects on serum electrolytes were observed during short- and long-term therapy.

Serum Glucose: No significant effects on fasting serum glucose were observed in patients treated with PLENDIL in the U.S. controlled study.

Liver Enzymes: One of two episodes of elevated serum transaminases decreased once drug was discontinued in clinical studies; no follow-up was available for the other patient.

OVERDOSAGE

Oral doses of 240 mg/kg and 264 mg/kg in male and female mice, respectively and 2390 mg/kg and 2250 mg/kg in male and female rats, respectively, caused significant lethality.

In a suicide attempt, one patient took 150 mg felodipine together with 15 tablets each of atenolol and spironolactone and 20 tablets of nitrazepam. The patient's blood pressure and heart rate were normal on admission to hospital; he subsequently recovered without significant sequelae.

Overdosage might be expected to cause excessive peripheral vasodilation with marked hypotension and possibly bradycardia.

If severe hypotension occurs, symptomatic treatment should be instituted. The patient should be placed supine with the legs elevated. The administration of intravenous fluids may be useful to treat hypotension due to overdosage with calcium antagonists. In case of accompanying bradycardia, atropine (0.5-1 mg) should be administered intravenously. Sympathomimetic drugs may also be given if the physician feels they are warranted.

It has not been established whether felodipine can be removed from the circulation by hemodialysis.

DOSAGE AND ADMINISTRATION

The recommended starting dose is 5 mg once a day. Depending on the patient's response the dosage can be decreased to 2.5 mg or increased to 10 mg once a day. These adjustments should occur generally at intervals of not less than two weeks. The recommended dosage range is 2.5-10 mg once daily. In clinical trials, doses above 10 mg showed an increased blood pressure response but a large increase in the rate of peripheral edema and other vasodilatory adverse events (see ADVERSE REACTIONS). Modification of the recommended dosage is usually not required in patients with renal impairment.

PLENDIL should be swallowed whole and not crushed or chewed.

Use in the Elderly or Patients with Impaired Liver Function: Patients over 65 years of age or patients with impaired liver function, because they may develop higher plasma concentrations of felodipine, should have their blood pressure monitored closely during dosage adjustment (see PRECAUTIONS). In general, doses above 10 mg should not be considered in these patients.



Dist. by:

ASTRA MERCK

Wayne, PA 19087, USA

Manufactured by: Merck & Co., Inc., West Point, PA 19486, USA

References:

1. Data on file (DA-PLN9), Astra Merck Inc.
2. Medi-Span, Inc., November 1994.


*Registered trademark of AB Astra
†Based on patient weight of 50 kg



ASTRA MERCK

ERASER

Go ahead.
Take a good hard look.



Plendil[®]

(felodipine) Tablets, 2.5 mg,
5 mg, 10 mg

Hypertension plus concomitant disorders?

First, do no harm.



PLENDIL – No significant effect on cardiac contractility. No significant effect on conductivity. No effect on cardiac output. No negative inotropic effect.*

PLENDIL – Suitable for a wide range of hypertensive patients, including those with hypercholesterolemia, arthritis, diabetes, impaired renal function, asthma or COPD.

PLENDIL – Few known drug interactions.†

PLENDIL – Worldwide experience: More than 800 million patient days worldwide.‡

PLENDIL – One of the least expensive dihydropyridine calcium channel blockers available today.‡

The most common unwanted effects are peripheral edema and headache.

24-hour control

Plendil®

(felodipine) Tablets, 2.5 mg,
5 mg, 10 mg

**Because you consider the
whole patient.**



ASTRA MERCK



* In clinical trials in hypertensive patients without clinical evidence of left ventricular dysfunction, no symptoms suggestive of a negative inotropic effect were noted; however, none would be expected in this population. Although acute hemodynamic studies in a small number of patients with NYHA Class II or III heart failure treated with felodipine have not demonstrated negative inotropic effects, safety in patients with heart failure has not been established.

† See PRECAUTIONS section of Prescribing Information.

‡ Based on the Average Wholesale Price (AWP) at the recommended starting dosages for each product. AWP is from a published price list and does not necessarily represent the actual price to pharmacists or consumers. Please see brief summary of Prescribing Information on the next page.

BRIEF SUMMARY

PLENDIL® (FLOPIDINE) EXTENDED-RELEASE TABLETS

Before prescribing, please consult full Prescribing Information.

INDICATIONS AND USAGE: PLENDIL* is indicated for the treatment of hypertension. PLENDIL may be used alone or concomitantly with other antihypertensive agents.

CONTRAINDICATIONS: PLENDIL is contraindicated in patients who are hypersensitive to this product.

PRECAUTIONS: General: Hypotension: Felodipine, like other calcium antagonists, may occasionally precipitate significant hypotension and rarely syncope. It may lead to reflex tachycardia which in susceptible individuals may precipitate angina pectoris. (See ADVERSE REACTIONS.)

Heart Failure: Although acute hemodynamic studies in a small number of patients with NYHA Class II or III heart failure treated with felodipine have not demonstrated negative inotropic effects, safety in patients with heart failure has not been established. Caution therefore should be exercised when using PLENDIL in patients with heart failure or compromised ventricular function, particularly in combination with a beta blocker.

Elderly Patients or Patients with Impaired Liver Function: Patients over 65 years of age or patients with impaired liver function may have elevated plasma concentrations of felodipine and may therefore respond to lower doses of PLENDIL. These patients should have their blood pressure monitored closely during dosage adjustment of PLENDIL and should rarely require doses above 10 mg. (See CLINICAL PHARMACOLOGY and DOSAGE AND ADMINISTRATION sections of complete Prescribing Information.)

Peripheral Edema: Peripheral edema, generally mild and not associated with generalized fluid retention, was the most common adverse event in the clinical trials. The incidence of peripheral edema was both dose- and age-dependent. Frequency of peripheral edema ranged from about 10 percent in patients under 50 years of age taking 5 mg daily to about 30 percent in those over 60 years of age taking 20 mg daily. This adverse effect generally occurs within 2-3 weeks of the initiation of treatment.

Information for Patients

Patients should be instructed to take PLENDIL whole and not to crush or chew the tablets. They should be told that mild gingival hyperplasia (gum swelling) has been reported. Good dental hygiene decreases its incidence and severity.

NOTE: As with many other drugs, certain advice to patients being treated with PLENDIL is warranted. This information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects.

Drug Interactions: Beta-Blocking Agents: A pharmacokinetic study of felodipine in conjunction with metoprolol demonstrated no significant effects on the pharmacokinetics of felodipine. The AUC and C_{max} of metoprolol, however, were increased approximately 31 and 38 percent, respectively. In controlled clinical trials, however, beta blockers including metoprolol were concurrently administered with felodipine and were well tolerated.

Cimetidine: In healthy subjects pharmacokinetic studies showed an approximately 50 percent increase in the area under the plasma concentration time curve (AUC) as well as the C_{max} of felodipine when given concomitantly with cimetidine. It is anticipated that a clinically significant interaction may occur in some hypertensive patients. Therefore, it is recommended that low doses of PLENDIL be used when given concomitantly with cimetidine.

Digoxin: When given concomitantly with felodipine the peak plasma concentration of digoxin was significantly increased. There was, however, no significant change in the AUC of digoxin.

Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (e.g., phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers. In such patients, the mean area under the felodipine plasma concentration-time curve was also reduced to approximately six percent of that observed in healthy volunteers. Since a clinically significant interaction may be anticipated, alternative antihypertensive therapy should be considered in these patients.

Other Concomitant Therapy: In healthy subjects there were no clinically significant interactions when felodipine was given concomitantly with indomethacin or spironolactone.

Interaction with Food: See CLINICAL PHARMACOLOGY, *Pharmacokinetics and Metabolism* section of complete Prescribing Information.

Carcinogenesis, Mutagenesis, Impairment of Fertility

In a two-year carcinogenicity study in rats fed felodipine at doses of 7.7, 23.1 or 69.3 mg/kg/day (up to 28 times' the maximum recommended human dose on a mg/m² basis), a dose-related increase in the incidence of benign interstitial cell tumors of the testes (Leydig cell tumors) was observed in treated male rats. These tumors were not observed in a similar study in mice at doses up to 138.6 mg/kg/day (28 times' the maximum recommended human dose on a mg/m² basis). Felodipine, at the doses employed in the two-year rat study, has been shown to lower testicular testosterone and to produce a corresponding increase in serum luteinizing hormone in rats. The Leydig cell tumor development is possibly secondary to these hormonal effects which have not been observed in man.

In this same rat study a dose-related increase in the incidence of focal squamous cell hyperplasia compared to control was observed in the esophageal groove of male and female rats in all dose groups. No other drug-related esophageal or gastric pathology was observed in the rats or with chronic administration in mice and dogs. The latter species, like man, has no anatomical structure comparable to the esophageal groove.

Felodipine was not carcinogenic when fed to mice at doses of up to 138.6 mg/kg/day (28 times' the maximum recommended human dose on a mg/m² basis) for periods of up to 80 weeks in males and 99 weeks in females.

Felodipine did not display any mutagenic activity *in vitro* in the Ames microbial mutagenicity test or in the mouse lymphoma forward mutation assay. No clastogenic potential was seen *in vivo* in the mouse micronucleus test at oral doses up to 2500 mg/kg (506 times' the maximum recommended human dose on a mg/m² basis) or *in vitro* in a human lymphocyte chromosome aberration assay.

A fertility study in which male and female rats were administered doses of 3.8, 9.6 or 26.9 mg/kg/day showed no significant effect of felodipine on reproductive performance.

Pregnancy: Pregnancy Category C

Teratogenic Effects: Studies in pregnant rabbits administered doses of 0.46, 1.2, 2.3 and 4.6 mg/kg/day (from 0.4 to 4 times' the maximum recommended human dose on a mg/m² basis) showed digital anomalies consisting of reduction in size and degree of ossification of the terminal phalanges in the fetuses. The frequency and severity of the changes appeared dose-related and were noted even at the lowest dose. These changes have been shown to occur with other members of the dihydropyridine class and are possibly a result of compromised uterine blood flow. Similar fetal anomalies were not observed in rats given felodipine.

In a teratology study in cynomolgus monkeys no reduction in the size of the terminal phalanges was observed but an abnormal position of the distal phalanges was noted in about 40 percent of the fetuses.

Nonteratogenic Effects: A prolongation of parturition with difficult labor and an increased frequency of fetal and early postnatal deaths were observed in rats administered doses of 9.6 mg/kg/day (4 times' the maximum human dose on a mg/m² basis) and above.

Significant enlargement of the mammary glands in excess of the normal enlargement for pregnant rabbits was found with doses greater than or equal to 1.2 mg/kg/day (equal to the maximum human dose on a mg/m² basis). This effect occurred only in pregnant rabbits and regressed during lactation. Similar changes in the mammary glands were not observed in rats or monkeys.

There are no adequate and well-controlled studies in pregnant women. If felodipine is used during pregnancy, or if the patient becomes pregnant while taking this drug, she should be apprised of the potential hazard to the fetus, possible digital anomalies of the infant, and the potential effects of felodipine on labor and delivery, and on the mammary glands of pregnant females.

Nursing Mothers

It is not known whether this drug is secreted in human milk and because of the potential for serious adverse reactions from felodipine in the infant, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use

Safety and effectiveness in children have not been established.

ADVERSE REACTIONS

In controlled studies in the United States and overseas approximately 3000 patients were treated with felodipine as either the extended-release or the immediate-release formulation.

The most common clinical adverse experiences reported with PLENDIL® (Felodipine) administered as monotherapy in all settings and with all dosage forms of felodipine were peripheral edema and headache. Peripheral edema was generally mild, but it was age- and dose-related and resulted in discontinuation of therapy in about 4 percent of the enrolled patients. Discontinuation of therapy due to any clinical adverse experience occurred in about 9 percent of the patients receiving PLENDIL, principally for peripheral edema, headache, or flushing.

Adverse experiences that occurred with an incidence of 1.5 percent or greater during monotherapy with PLENDIL without regard to causality are compared to placebo in the table below.

Percent of Patients with Adverse Effects in Controlled Trials of PLENDIL as Monotherapy (Incidence of discontinuations shown in parentheses)

Adverse Effect	PLENDIL % N = 730	Placebo % N = 283
Peripheral Edema	22.3 (4.2)	3.5
Headache	18.6 (2.1)	10.6
Flushing	6.4 (1.0)	1.1
Dizziness	5.8 (0.8)	3.2
Upper Respiratory Infection	5.5 (0.1)	1.1
Asthenia	4.7 (0.1)	2.8
Cough	2.9 (0.0)	0.4
Paresthesia	2.5 (0.1)	1.8
Dyspepsia	2.3 (0.0)	1.4
Chest Pain	2.1 (0.1)	1.4
Nausea	1.9 (0.8)	1.1
Muscle Cramps	1.9 (0.0)	1.1
Palpitation	1.8 (0.5)	2.5
Abdominal Pain	1.8 (0.3)	1.1
Constipation	1.6 (0.1)	1.1
Diarrhea	1.6 (0.1)	1.1
Pharyngitis	1.6 (0.0)	0.4
Rhinorrhea	1.6 (0.0)	0.4
Back Pain	1.6 (0.0)	1.1
Rash	1.5 (0.1)	1.1

In the two dose response studies using PLENDIL as monotherapy, the following table describes the incidence (percent) of adverse experiences that were dose-related. The incidence of discontinuations due to these adverse experiences are shown in parentheses.

Adverse Effect	Placebo N = 121	2.5 mg N = 71	5.0 mg N = 72	10.0 mg N = 123	20 mg* N = 50
Peripheral Edema	2.5 (1.6)	1.4 (0.0)	13.9 (2.8)	19.5 (2.4)	36.0 (10.0)
Palpitation	0.8 (0.8)	1.4 (0.0)	0.0 (0.0)	2.4 (0.8)	12.0 (8.0)
Headache	12.4 (0.0)	11.3 (1.4)	11.1 (0.0)	18.7 (4.1)	28.0 (18.0)
Flushing	0.0 (0.0)	4.2 (0.0)	2.8 (0.0)	8.1 (0.8)	20.0 (8.0)

*exceeds the maximum recommended daily dose.

In addition, adverse experiences that occurred in 0.5 up to 1.5 percent of patients who received PLENDIL® (Felodipine) in all controlled clinical studies (listed in order of decreasing severity within each category) and serious adverse events that occurred at a lower rate or were found during marketing experience (those lower rate events are in italics) were: *Body as a Whole:* Facial edema, warm sensation; *Cardiovascular:* Tachycardia, myocardial infarction, hypotension, syncope, angina pectoris, arrhythmia; *Digestive:* Vomiting, dry mouth, flatulence; *Hematologic:* Anemia; *Musculoskeletal:* Arthralgia, arm pain, knee pain, leg pain, foot pain, hip pain, myalgia; *Nervous/Psychiatric:* Depression, anxiety disorders, insomnia, irritability, nervousness, somnolence; *Respiratory:* Bronchitis, influenza, sinusitis, dyspnea, epistaxis, respiratory infection, sneezing; *Skin:* Contusion, erythema, urticaria; *Urogenital:* Decreased libido, impotence, urinary frequency, urinary urgency, dysuria.

Felodipine, as an immediate release formulation, has also been studied as monotherapy in 680 patients with hypertension in U.S. and overseas controlled clinical studies. Other adverse experiences not listed above and with an incidence of 0.5 percent or greater include: *Body as a Whole:* Fatigue; *Digestive:* Gastrointestinal pain; *Musculoskeletal:* Arthritis, local weakness, neck pain, shoulder pain, ankle pain; *Nervous/Psychiatric:* Tremor; *Respiratory:* Rhinitis; *Skin:* Hyperhidrosis, pruritus; *Special Senses:* Blurred vision, tinnitus; *Urogenital:* Nocturia.

Gingival Hyperplasia: Gingival hyperplasia, usually mild, occurred in <0.5 percent of patients in controlled studies. This condition may be avoided or may regress with improved dental hygiene. (See PRECAUTIONS, *Information for Patients.*)

Clinical Laboratory Test Findings

Serum Electrolytes: No significant effects on serum electrolytes were observed during short- and long-term therapy.

Serum Glucose: No significant effects on fasting serum glucose were observed in patients treated with PLENDIL in the U.S. controlled study.

Liver Enzymes: One of two episodes of elevated serum transaminases decreased once drug was discontinued in clinical studies; no follow-up was available for the other patient.

OVERDOSAGE

Oral doses of 240 mg/kg and 264 mg/kg in male and female mice, respectively and 2390 mg/kg and 2250 mg/kg in male and female rats, respectively, caused significant lethality.

In a suicide attempt, one patient took 150 mg felodipine together with 15 tablets each of atenolol and spironolactone and 20 tablets of nitrazepam. The patient's blood pressure and heart rate were normal on admission to hospital; he subsequently recovered without significant sequelae.

Overdosage might be expected to cause excessive peripheral vasodilation with marked hypotension and possibly bradycardia.

If severe hypotension occurs, symptomatic treatment should be instituted. The patient should be placed supine with the legs elevated. The administration of intravenous fluids may be useful to treat hypotension due to overdosage with calcium antagonists. In case of accompanying bradycardia, atropine (0.5-1 mg) should be administered intravenously. Sympathomimetic drugs may also be given if the physician feels they are warranted.

It has not been established whether felodipine can be removed from the circulation by hemodialysis.

DOSAGE AND ADMINISTRATION

The recommended starting dose is 5 mg once a day. Depending on the patient's response the dosage can be decreased to 2.5 mg or increased to 10 mg once a day. These adjustments should occur generally at intervals of not less than two weeks. The recommended dosage range is 2.5-10 mg once daily. In clinical trials, doses above 10 mg showed an increased blood pressure response but a large increase in the rate of peripheral edema and other vasodilatory adverse events (see ADVERSE REACTIONS). Modification of the recommended dosage is usually not required in patients with renal impairment.

PLENDIL should be swallowed whole and not crushed or chewed.

Use in the Elderly or Patients with Impaired Liver Function: Patients over 65 years of age or patients with impaired liver function, because they may develop higher plasma concentrations of felodipine, should have their blood pressure monitored closely during dosage adjustment (see PRECAUTIONS). In general, doses above 10 mg should not be considered in these patients.



Dist. by:

ASTRA MERCK

Wayne, PA 19087, USA

Manufactured by: Merck & Co., Inc., West Point, PA 19486, USA

References:

1. Data on file (DA-PLN9), Astra Merck Inc.
2. Medi-Span, Inc., November 1994.


*Registered trademark of AB Astra
†Based on patient weight of 50 kg

In Patients Over 65

NEW
2.5 mg
Starting
Dose

Hypertension plus concomitant disorders?

First, do no harm.



PLENDIL – No significant effect on cardiac contractility. No significant effect on conductivity. No effect on cardiac output. No negative inotropic effect.*

PLENDIL – Suitable for a wide range of hypertensive patients, including those with hypercholesterolemia, arthritis, diabetes, impaired renal function, asthma or COPD.

PLENDIL – Few known drug interactions.†

PLENDIL – Worldwide experience: More than 800 million patient days worldwide.‡

PLENDIL – One of the least expensive dihydropyridine calcium channel blockers available today.‡2

The most common unwanted effects are peripheral edema and headache.

24-hour control

Plendil®

(felodipine) Tablets, 2.5 mg,
5 mg, 10 mg

**Because you consider the
whole patient.**



ASTRA MERCK

*In clinical trials in hypertensive patients without clinical evidence of left ventricular dysfunction, no symptoms suggestive of a negative inotropic effect were noted; however, none would be expected in this population. Although acute hemodynamic studies in a small number of patients with NYHA Class II or III heart failure treated with felodipine have not demonstrated negative inotropic effects, safety in patients with heart failure has not been established.

†See PRECAUTIONS section of full Prescribing Information.

‡Based on the Average Wholesale Price (AWP) at the recommended starting dosages for each product. AWP is from a published price list and does not necessarily represent the actual price to pharmacists or consumers. Please see brief summary of Prescribing Information on the next page.

For hypertensive patients with concomitant disorders.

24-hour control



Plendil®

(felodipine) Tablets, 2.5 mg, 5 mg, 10 mg



Because you consider the whole patient.

NEW LABELING

BRIEF SUMMARY

PLENDIL® (FELODIPINE) EXTENDED-RELEASE TABLETS

Before prescribing, please consult full Prescribing Information.

CONTRAINDICATIONS: Hypersensitivity to this product.

PRECAUTIONS: General: Hypotension: May occasionally precipitate significant hypotension and rarely syncope. May lead to reflex tachycardia which in susceptible individuals may precipitate angina pectoris. (See ADVERSE REACTIONS.)

Heart Failure: Although acute hemodynamic studies in a small number of patients with NYHA Class II or III heart failure treated with felodipine have not demonstrated negative inotropic effects, safety in patients with heart failure has not been established. Caution therefore should be exercised when using PLENDIL® in patients with heart failure or compromised ventricular function, particularly in combination with a beta blocker.

Elderly Patients or Patients with Impaired Liver Function: Patients over 65 years of age or patients with impaired liver function may have elevated plasma concentrations of felodipine and may respond to lower doses of PLENDIL, therefore a starting dose of 2.5 mg once a day is recommended. These patients should have their blood pressure monitored closely during dosage adjustment of PLENDIL. (See CLINICAL PHARMACOLOGY and DOSAGE AND ADMINISTRATION sections of full Prescribing Information.)

Peripheral Edema: Peripheral edema, generally mild and not associated with generalized fluid retention, was the most common adverse event in the clinical trials. The incidence of peripheral edema was both dose- and age-dependent. Frequency of peripheral edema ranged from about 10 percent in patients under 50 years of age taking 5 mg daily to about 30 percent in those over 60 years of age taking 20 mg daily. This adverse effect generally occurs within 2-3 weeks of the initiation of treatment.

Information for Patients

Take PLENDIL tablets whole; do not crush or chew. Patients should be told that mild gingival hyperplasia (gum swelling) has been reported. Good dental hygiene decreases its incidence and severity.

Drug Interactions: Beta-Blocking Agents: A pharmacokinetic study of felodipine in conjunction with metoprolol demonstrated no significant effects on the pharmacokinetics of felodipine. The AUC and C_{max} of metoprolol, however, were increased approximately 31 and 38 percent, respectively. In controlled clinical trials, however, beta blockers including metoprolol were concurrently administered with felodipine and were well tolerated.

Cimetidine: In healthy subjects pharmacokinetic studies showed an approximately 50 percent increase in the area under the plasma concentration-time curve (AUC) as well as the C_{max} of felodipine when given concomitantly with cimetidine. It is anticipated that a clinically significant interaction may occur in some hypertensive patients. Therefore, it is recommended that low doses of PLENDIL be used when given concomitantly with cimetidine.

Digoxin: When given concomitantly with PLENDIL the pharmacokinetics of digoxin in patients with heart failure were not significantly altered.

Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (e.g., phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers. In such patients, the mean area under the felodipine plasma concentration-time curve was also reduced to approximately six percent of that observed in healthy volunteers. Since a clinically significant interaction may be anticipated, alternative antihypertensive therapy should be considered in these patients.

Other Concomitant Therapy: In healthy subjects there were no clinically significant interactions when felodipine was given concomitantly with indomethacin or spironolactone.

Interaction with Food: See CLINICAL PHARMACOLOGY, Pharmacokinetics and Metabolism section of full Prescribing Information.

Carcinogenesis, Mutagenesis, Impairment of Fertility

In a two-year carcinogenicity study in rats fed felodipine at doses of 7.7, 23.1 or 69.3 mg/kg/day (up to 28 times the maximum recommended human dose on a mg/m² basis), a dose-related increase in the incidence of benign interstitial cell tumors of the testes (Leydig cell tumors) was observed in treated male rats. These tumors were not observed in a similar study in mice at doses up to 138.6 mg/kg/day (28 times the maximum recommended human dose on a mg/m² basis). Felodipine, at the doses employed in the two-year rat study, has been shown to lower testicular testosterone and to produce a corresponding increase in serum luteinizing hormone in rats. The Leydig cell tumor development is possibly secondary to these hormonal effects which have not been observed in man.

In this same rat study a dose-related increase in the incidence of focal squamous cell hyperplasia compared to control was observed in the esophageal groove of male and female rats in all dose groups. No other drug-related esophageal or gastric pathology was observed in the rats or with chronic administration in mice and dogs. The latter species, like man, has no anatomical structure comparable to the esophageal groove.

Felodipine was not carcinogenic when fed to mice at doses of up to 138.6 mg/kg/day (28 times the maximum recommended human dose on a mg/m² basis) for periods of up to 80 weeks in males and 99 weeks in females.

Felodipine did not display any mutagenic activity *in vitro* in the Ames microbial mutagenicity test or in the mouse lymphoma forward mutation assay. No clastogenic potential was seen *in vivo* in the mouse micronucleus test at oral doses up to 2500 mg/kg (506 times the maximum recommended human dose on a mg/m² basis) or *in vitro* in a human lymphocyte chromosome aberration assay.

A fertility study in which male and female rats were administered doses of 3.8, 9.6 or 26.9 mg/kg/day showed no significant effect of felodipine on reproductive performance.

Pregnancy: Pregnancy Category C

There are no adequate and well-controlled studies in pregnant women. If felodipine is used during pregnancy, or if the patient becomes pregnant while taking this drug, she should be apprised of the potential hazard to the fetus, possible digital anomalies of the infant, and the potential effects of felodipine on labor and delivery, and on the mammary glands of pregnant females. (See FULL PRESCRIBING INFORMATION.)

Nursing Mothers

It is not known whether this drug is secreted in human milk and because of the potential for serious adverse reactions from felodipine in the infant, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use

Safety and effectiveness in children have not been established.

ADVERSE REACTIONS: In controlled studies in the United States and overseas approximately 3000 patients were treated with felodipine as either the extended-release or the immediate-release formulation.

The most common clinical adverse events reported with PLENDIL® (felodipine) administered as monotherapy at the recommended dosage range of 2.5 mg to 10 mg once a day were peripheral edema and headache. Peripheral edema was generally mild, but it was age- and dose-related and resulted in discontinuation of therapy in about 3 percent of the enrolled patients. Discontinuation of therapy due to any clinical adverse event occurred in about 6 percent of the patients receiving PLENDIL, principally for peripheral edema, headache, or flushing.

Adverse events that occurred with an incidence of 1.5 percent or greater at any of the recommended doses of 2.5 mg to 10 mg once a day (PLENDIL, N=861; Placebo, N=334), without regard to causality, are compared to placebo and are listed by dose in the table below. These events are reported from controlled clinical trials with patients who were randomized to a fixed dose of PLENDIL or titrated from an initial dose of 2.5 mg or 5 mg once a day. A dose of 20 mg once a day has been evaluated in some clinical studies. Although the antihypertensive effect of PLENDIL is increased at 20 mg once a day, there is a disproportionate increase in adverse events, especially those associated with vasodilatory effects (see DOSAGE AND ADMINISTRATION).

Starting dose: 5 mg once a day.
2.5 mg once a day for patients over 65 and patients with liver impairment.

Most commonly dispensed dose³:
5 mg once a day.

Recommended dosage range:

2.5 mg to 10 mg once a day.

PLENDIL should be swallowed whole and not crushed or chewed.

References:

1. Data on file, DA-PLN9.
2. Medi-Span, Inc., June 1995.
3. IMS NPA Plus™ May 1995 prescription data; Data on file, DA-PLN8.

Percent of Patients with Adverse Events in Controlled Trials* of PLENDIL (N=861) as Monotherapy without Regard to Causality (Incidence of discontinuations shown in parentheses)

Body System Adverse Events	Placebo N=334	2.5 mg N=255	5 mg N=581	10 mg N=408
Body as a Whole				
Peripheral Edema	3.3 (0.0)	2.0 (0.0)	8.8 (2.2)	17.4 (2.5)
Asthenia	3.3 (0.0)	3.9 (0.0)	3.3 (0.0)	2.2 (0.0)
Warm Sensation	0.0 (0.0)	0.0 (0.0)	0.9 (0.2)	1.5 (0.0)
Cardiovascular				
Palpitation	2.4 (0.0)	0.4 (0.0)	1.4 (0.3)	2.5 (0.5)
Digestive				
Nausea	1.5 (0.9)	1.2 (0.0)	1.7 (0.3)	1.0 (0.7)
Dyspepsia	1.2 (0.0)	3.9 (0.0)	0.7 (0.0)	0.5 (0.0)
Constipation	0.9 (0.0)	1.2 (0.0)	0.3 (0.0)	1.5 (0.2)
Nervous				
Headache	10.2 (0.9)	10.6 (0.4)	11.0 (1.7)	14.7 (2.0)
Dizziness	2.7 (0.3)	2.7 (0.0)	3.6 (0.5)	3.7 (0.5)
Paresthesia	1.5 (0.3)	1.6 (0.0)	1.2 (0.0)	1.2 (0.2)
Respiratory				
Upper Respiratory Infection	1.8 (0.0)	3.9 (0.0)	1.9 (0.0)	0.7 (0.0)
Cough	0.3 (0.0)	0.8 (0.0)	1.2 (0.0)	1.7 (0.0)
Rhinorrhoea	0.0 (0.0)	1.6 (0.0)	0.2 (0.0)	0.2 (0.0)
Sneezing	0.0 (0.0)	1.6 (0.0)	0.0 (0.0)	0.0 (0.0)
Skin				
Rash	0.9 (0.0)	2.0 (0.0)	0.2 (0.0)	0.2 (0.0)
Flushing	0.9 (0.3)	3.9 (0.0)	5.3 (0.7)	6.9 (1.2)

*Patients in titration studies may have been exposed to more than one dose level of PLENDIL® (felodipine).

Adverse events that occurred in 0.5 up to 1.5 percent of patients who received PLENDIL in all controlled clinical trials at the recommended dosage range of 2.5 mg to 10 mg once a day and serious adverse events that occurred at a lower rate or events reported during marketing experience (those lower rate events are in italics) are listed below. These events are listed in order of decreasing severity within each category and the relationship of these events to administration of PLENDIL is uncertain: **Body as a Whole:** Chest pain, facial edema, flu-like illness; **Cardiovascular:** Myocardial infarction, hypotension, syncope, angina pectoris, arrhythmia, tachycardia, premature beats; **Digestive:** Abdominal pain, diarrhea, vomiting, dry mouth, flatulence, acid regurgitation; **Hematologic:** Anemia; **Metabolic:** ALT (SGPT) increased; **Musculoskeletal:** Arthralgia, back pain, leg pain, foot pain, muscle cramps, myalgia, arm pain, knee pain, hip pain; **Nervous/Psychiatric:** Insomnia, depression, anxiety disorders, irritability, nervousness, somnolence, decreased libido; **Respiratory:** Dyspnea, pharyngitis, bronchitis, influenza, sinusitis, epistaxis, respiratory infection; **Skin:** Contusion, erythema, urticaria; **Special Senses:** Visual disturbances; **Urogenital:** Impotence, urinary frequency, urinary urgency, dysuria, polyuria.

Gingival Hyperplasia: Gingival hyperplasia, usually mild, occurred in <0.5 percent of patients in controlled studies. This condition may be avoided or may regress with improved dental hygiene. (See PRECAUTIONS, Information for Patients section.)

Clinical Laboratory Test Findings

Serum Electrolytes: No significant effects on serum electrolytes were observed during short- and long-term therapy. (See CLINICAL PHARMACOLOGY, Renal/Endocrine Effects section of full Prescribing Information.)

Serum Glucose: No significant effects on fasting serum glucose were observed in patients treated with PLENDIL in the U.S. controlled study.

Liver Enzymes: One of two episodes of elevated serum transaminases decreased once drug was discontinued in clinical studies; no follow-up was available for the other patient.



Distributed by:

ASTRA MERCK

Wayne, PA 19087, USA

Manufactured by: MERCK & Co., Inc.
West Point, PA 19486, USA

* Registered trademark of Astra AB.

¹ Based on patient weight of 50 kg